Sales to outside customers increased significantly to 20,769 million yen
(up 11.9% year-on-year).
Sales of OTC eye drops were strong in the U.S. and Hydrox Laboratories,
which manufactures and sells medical disinfectants and other products,
continued to perform strongly. In addition, our consolidated subsidiaries
in Brazil, which experienced strong sales for "Hadalabo", also
made a contribution to the increase in sales.
Segment profit (operating income basis) increased significantly to 1,542
million yen (up 27.9% year-on-year) owing to profit improvements at Hydrox
Laboratories and the consolidated subsidiaries in Brazil.